Shopping Cart
- Remove All
- Your shopping cart is currently empty
Rimegepant, also known as BMS-927711 and BHV-3000, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraines. Rimegepant has shown in vivo efficacy without vasoconstriction effect. BMS-927711 is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,870 | 10-14 weeks | |
50 mg | $3,780 | 10-14 weeks | |
100 mg | $5,200 | 10-14 weeks |
Description | Rimegepant, also known as BMS-927711 and BHV-3000, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraines. Rimegepant has shown in vivo efficacy without vasoconstriction effect. BMS-927711 is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile. |
Molecular Weight | 1221.2526 |
Formula | C56H64F4N12O13S |
Cas No. | 1374024-48-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.